麗珠醫藥(01513.HK)註銷2022年股票期權激勵計劃下的股票期權
格隆匯5月6日丨麗珠醫藥(01513.HK)公告,於2025年4月23日,公司擬註銷首次授予股票期權第一個行權期尚未行權的股票期權38.4045萬份、首次授予股票期權第三個行權期對應的股票期權528.3750萬份和預留授予股票期權第二個行權期對應的股票期權100.00萬份。
2025年5月6日,經中國證券登記結算有限責任公司深圳分公司審覈確認,上述股票期權註銷事宜已辦理完畢。本次註銷完成後,首次授予及預留授予項下不再有剩餘的股票期權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.